The Home of the Life Sciences Industry

Pictured: Boehringer Ingelheim's building in Calif

Boehringer Inks Potential $2B Deal with Ribo, Targets NASH-MASH with siRNA Therapies

In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
Map of NextGen Class of 2024/BioSpace

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year

Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.

168极速赛车开奖记录查询 极速赛车168历史开奖结果彩票开奖网 极速赛车168开奖官网开奖直播 Hotbeds